Shanghai Escugen Biotechnology Co., Ltd. was established in 2017 in Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, focusing on the R&D of innovative drugs for oncology and autoimmune diseases. The founding team has decades of industrial R&D experience in top-tier biopharmaceutical companies of both international and domestic. The expertise of the team covers the whole multi-functional drug development processes, including antibody engineering, bio-conjugation technology, CMC, and clinical development.
The EZWi-Fit? linker-payload technology is an ADC technical platform invented by Escugen. Its global intellectual property is wholly owned by Escugen. The clinical safety and efficacy of ADCs based on this platform have been initially verified by the clinical trials currently being carried out by Escugen. Recently, ADCs against innovative targets based on this platform developed by a number of domestic and foreign partners have also successively entered the clinical trial stage.
EZWi-Fit? Technology Platform employs stable-cleavable linkers and a Topoisomerase I (TopI) inhibitor payload. ADCs generated using this platform demonstrate significantly higher in vivo activity against multiple therapeutic targets compared to ADCs with other TopI inhibitors as payloads in various preclinical models.
mAb Drugs
?
ADC Drugs
